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The MDR1 P-glycoprotein (P-gp) actively extrudes a wide variety of structurally diverse cytotoxic compounds out of the cell, is widely
expressed in the epithelial cells of kidney, liver and intestine, and in the endothelial cells of brain and placenta, and plays an important role in drug
resistance. We measured the accumulation of Rhodamine 123 (Rho123), a substrate of P-gp, into a drug sensitive and a drug resistant strain of the
human leukemia cell line K562, as function of Rho123 concentration. With the aid of a mathematical transformation, we used the accumulation of
Rho123 into the sensitive cells as a surrogate measure for the internal concentration of the probe in the resistant cells, and were thus able
to measure the kinetic parameters of drug efflux pumping by P-gp. Drug pumping was half-saturated at an external Rho123 concentration of
7.2E–06±1.1E–06 M, and displayed a co-operative behaviour with a Hill number of 1.94±0.32. Verapamil could be shown to inhibit Rho123
efflux uncompetitively.
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The MDR1 P-glycoprotein (P-gp) actively extrudes a wide
variety of structurally diverse cytotoxic compounds out of the
cell. P-gp is widely expressed in the epithelial cells of kidney,
liver and intestine, and in the endothelial cells of brain and
placenta [1]. P-gp transports a wide variety of drugs out of
the cell in an energy-dependent manner, and has also been
implicated in multidrug resistance found during cancer and
AIDS chemotherapy [2]. The broad substrate specificity and
wide expression of P-gp makes it play a very important role in
the regulation of ADME (drug absorption, distribution,
metabolism and excretion) [1], and has made it a target of
intense investigation. The arrangement of the domains in P-gp in
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doi:10.1016/j.bbamem.2006.06.004atomic resolution structural information has been available for
P-gp until now [3] due to its low abundance, difficult purifi-
cation, membrane location, and the lack of a high-expression
system [4]. Thus data are very limited on the interaction mech-
anism between P-gp and its substrates, information which is of
crucial importance both in the development of MDR reversers
and in decision-making with regard to drug candidates. The
number and the primary structure of the binding sites of
substrates and inhibitors in P-gp have been reported. However,
the data were mostly acquired from P-gp binding and P-gp
ATPase activity, such as photolabeling, cysteine-scanning
mutagenesis, and P-gp ATPase determination [5,6], rather than
from P-gp transport. The kinetic study of P-gp transport thus
provides a useful additional approach to understand the inter-
action mechanism between P-gp and compounds, when atomic
resolution structural information for P-gp is not available. In the
present paper, we introduce a kinetic approach to study P-gp
transport, based on the influx of Rhodamine 123 (Rho123), a
much-used probe for P-gp. We confirm that P-gp is an effective
efflux transporter of Rho123 and show that there is co-operative
interaction between Rho123 molecules (probably in pairs) as they
bind to P-gp during efflux pumping. We estimate the apparent
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diminishes the rate of efflux pumping and does so in an un-
competitive fashion.
In our experiments, we have used K562 cells, a human leu-
kemia cell line, established from a patient with chronic myelo-
geneous leukemia. K562/ADR cells resistant to doxorubicin were
obtained by continuous exposure to increasing doxorubicin con-
centrations [7]. The K562/ADM subline expresses P-gp at the
membrane surface at a high level, whereas the parent line does
not. Indeed, a recent single cell immunoassay study using cap-Fig. 1illary electrophoresis with laser induced fluorescence detection
suggests that the resistant subline we use possesses some four
times as much PgP as does the parent, sensitive line [8]. The
parent line (K562/S), which is sensitive to doxorubicin, has been
used as a negative control against the K562 drug resistant subline
in a P-gp related study [7].
In order to avoid possible complications in data analysis that
can arise due to the self-quenching of Rho123 within the loaded
cells, we have developed a method in which the drug sensitive
cells are used to provide a calibration curve for the amount of.
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probe. This enables us to calculate, for the resistant cells, the
relative amount of probe that has been pumped out of the cells.
We use this to obtain a measure of the fraction of the probe that
is pumped out of the cell, at any level of external Rho123. It is
from this fraction and its dependence on the level of external
probe that we derive the kinetic data for Rho123 pumping.
2. Materials and methods
2.1. Materials
R-(+)-Verapamil and Rhodamine123 were purchased from Sigma. All the
other chemicals were reagent grade and were obtained commercially.
2.2. Cell culture
Both the drug-sensitive K562 (K562/S) cell line and the doxorubicin-resistant
cell subline (K562/ADR) were purchased from the Tianjin Institute of Hemato-
pathy. K562/A and K562/S cells were cultured in PRMI1640(Gibco) medium,
supplemented with 10% fetal bovine serums at 37 °C in a humidified incubator
with 5% CO2.
2.3. Rho123 influx
An initial influx study was performed in pH 7.4 standard phosphate buffered
saline (PBS) supplemented with 0.63 mM CaCl2, 0.74 mM MgSO4, 5.3 mM
glucose and 0.1 mM ascorbic acid (PBSA) [9]. Cells (K562/A and K562/S) were
distributed into 6 tubes at a density of 4×105 cells/ml (0.5ml per tube). Then they
were loaded with Rho123 at a concentration of 8.92 μM. Influx was stopped by
centrifugation, at 0.5min, 5min, 10min, 15min, 20min, and 25min and the cells
were then washed twice with ice-cold PBS containing Verapamil 100 μM.Fig. 2Controls without Rho123 were used to define fluorescence thresholds. A total of
5000 events were acquired per sample. Flow cytometric analysis of Rho123
fluorescence at 585 nm was carried out with the Fluorescence Activated Cell
Analyser (FACS Vantange, Becton Dickinson, San Jose, CA) with Cell Quest
software (Becton Dickinson Immunocytometry Systems, San Jose, CA).
For the determination of the kinetic parameters of Rho123 transport by P-gp
and the interaction mechanism of verapamil with P-gp, both K562/A and K562/S
cells were incubated at 37 °C at a density of 4×105 cells/ml (0.5 ml per tube) and
loaded with Rho123 (the concentration of Rho123 ranged from 8.92 μM to
41.99 μM) . To some samples of the K562/ADR cells, 0.10 μMol/L verapamil was
added at the same time.The cells were incubated at 37 °C for 5min, centrifuged and
washed twice with ice-cold PBS containing Verapamil 100 μM. Controls without
Rho123 were used to define fluorescence thresholds. Rho123 were determined by
flow cytometry as indicated above. In all cases, the fluorescence data are reported
here as the median fluorescence of the data output plotted as a histogram.
2.4. Data analysis
The data on the uptake of Rho123, measured as the median fluorescence as
described above, plotted as a function of the external concentration of probe for
the drug sensitive cells, were fitted by the simple hyperbolic equation:
F ¼ Fmax*S=ðS þ K1=2Þ ð1Þ
where S is the external concentration of Rho 123, F is the median fluorescence,
measured as described above, Fmax is the extrapolatedmaximum fluorescence and
K½ is the concentration of Rho123 at which one-half of the maximum fluorescence
is reached. This provides a calibration curve for subsequent studies using the drug-
resistant cells. Eq. (1) transforms simply to yield S at any F as:
S ¼ Fmax*K1=2=ðF−FmaxÞ ð2Þ
Thus using the values of Fmax and K½ found from the calibration curve using
the drug-sensitive cells, with measured values ofF found for the drug-resistant cells,
incubated at concentration S, we can estimate the external probe concentration, Sres,
that, for the sensitive cells, would give the same flow cytometry signal. We do not.
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some factor, α, times the external probe concentration. The factor α will depend on
the binding constant for Rho123 to its internal binding sites and on the amount of
such sites present per cell. At any external concentration S, the amount of probe
inside the cell will be given byαS. But Sres is the external probe concentration in the
sensitive cells that gives the same fluorescence signal (and hence the same internal
probe concentration) as that found when resistant cells are incubated with probe at
concentration S. Thus the internal concentration of probe in the resistant cells is
αSres. Subtracting αSres from αS yields the relative decrease in internal probe
concentration due to pumping. Finally, (α S-α Sres)/α S is the fraction of probe that
is pumped out of the cells in the drug-resistant cells, when these are incubated with
probe at external concentration S. Since α is, by assumption, everywhere the same,
this reduces to (S−Sres)/S, which are all now known or measurable quantities. We
can then plot this fraction against S to analyze the concentration dependence of the
effectiveness of the drug pump.3. Results
Uptake of Rho123 by the drug-sensitive cells was linear with
time for up to 10min (data not shown). For the kinetic studies the
incubation times with probe were thus set at 5 min to ensure that
initial rates were being measured. Fig. 1 S, A, and A+V depict
the fluorescence scans at this time for the three conditions,
sensitive cells, resistant cells, and resistant cells in the presence
of verapamil, as a function of the concentration of Rho123.
Fig. 2A depicts a plot of the median value of the
fluorescence signal, after 5 min of incubation, as measured in
Materials and methods, against the external probe concentration
for the drug-sensitive cells (filled circles) and drug-resistant
cells (empty circles). At every probe concentration, the
fluorescence signal for the resistant cells is lower than that for
the sensitive cells, consistent with the ability of P-gp to bring
about efflux of Rho123 from the resistant cells. The data for the
sensitive cells appear to lie on a saturation curve. This would be
consistent with the cells having a limited capacity for uptake of
Rho 123, but this is contradicted by the fact that in theFig. 3preliminary time course study, probe uptakes at 25 min were
more than three fold those at 5 min, so a limited binding
capacity is not the explanation of the apparent saturation found
for the sensitive cells in Fig. 1A. Self-quenching of fluorescent
probes is a well-studied phenomenon and would give results
similar to those of Fig. 2A. Assuming self-quenching to be
present, we used the data for the sensitive cells as a calibration
curve for estimating the effect of drug pumping in the resistant
cells. Curve fitting a simple ligand-binding equation (Eq. (1) of
Materials and methods) to the data yielded the operative kinetic
parameters of
Fmax ¼ 1015þ =−58
K1=2 ¼ 1:65E−005þ =−2:02E−006,
which were used to derive the equivalent probe concentration,
from the data plot for the resistant cells (open symbols in Fig. 2A),
usingEq. (2), as described inMaterials andmethods. From this, the
fraction pumped out at each probe concentration was calculated
(see Materials and methods) and these results plotted against the
respective probe concentration, in Fig. 2B. An attempt to fit these
data to a simple binding-ligand failed. A good fit was obtained,
however, using the co-operative kinetics for the Hill plot, yielding
the solid line in Fig. 2B, with parameters Rsq=0.981, maximum
fraction pumped of 0.725±0.014, Km for binding of 5.47E–06±
3.59E–07 and a Hill number of 2.43±0.43. Three similar ex-
periments yielded mean values for the maximum pumped fraction
of 0.76±0.02, for the Km for binding of 7.2E–06±1.1E–06, and
for the Hill number of 1.94±0.32, with each mean value being
followed by its SE (n=3).
Fig. 3 depicts two additional experiments where verapamil at
0.1 μ M is added to the drug resistant cells in the incubation
medium during probe uptake (middle curve, the triangles, in each.
Fig. 4.
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at each probe concentration, consistent with its reported ability to
block pumping of P-gp substrates (such as Rho123). Analyzing
the data as for Fig. 2 yielded the fraction of probe pumped at each
probe concentration. These are plotted in Fig. 4, for the points
obtained in the absence of verapamil (filled circles) or when
verapamil is present (empty circles). The fraction of drug pumped
is always lower when verapamil is added. Fitting the data in each
case to the Hill equation yielded the pump parameters listed in the
figure legend. In both experiments the Hill number and probe
binding parameter is not affected by verapamil, but the maximum
amount of probe pumped is reduced 11±0.5% by the addition of
0.1 μM verapamil. This gives a Ki for verapamil of 1.1 μM.
4. Discussion
We have developed a simple algorithm that enables data on
the uptake of Rho123 as a function of concentration in drug-
sensitive and -resistant cells to be interpreted in terms of the
kinetics of Rho123 pumping by P-gp. Our experimental data
and its analysis confirm that P-gp can bring about the efflux of
Rho123 from drug-resistant cells. Additionally, it would appear
from our data that two molecules of Rho123 interact co-opera-
tively during drug efflux and that verapamil is an effective
inhibitor of the drug pumping process, affecting the maximum
rate of transport but not the apparent affinity between Rho123and P-gp. The maximum amount of Rho123 pumped out of the
cells is about 75% of the total, in these cells and under our
conditions. The apparent affinity of Rho123 for P-gp is some
7.2 μM, in terms of the external probe concentration. How do
these points compare with previous studies of P-gp?
As a widely expressed transporter, P-gp transports an enor-
mous variety of chemical compounds from interior to exterior of
cells actively. Previous research discovered that P-gp plays an
important role in the regulation of drug ADME properties [1]
and is frequently responsible for multi-drug resistance during
cancer chemotherapy [2]. But how P-gp interacts with so many
kinds of chemicals still remains unknown. Key steps in under-
tanding the transport process are binding of drug substrates
within the transmembrane domains, initiation of ATPase ac-
tivity, and subsequent drug efflux [10]. Photolabeling and cys-
teine-scanning mutagenesis in combination with a thiol-specific
substrate have been widely employed in research concerning the
binding sites of the substrate in P-gp, and play a crucial role in
the identification of the number and location of its substrate
binding sites [5,6,11]. It appears that there is a common sub-
strate-binding pocket in P-gp, which is large enough to ac-
commodate different substrates simultaneously. The substrates
occupy different regions in the common drug-binding pocket.
The binding of substrates with P-gp induces conformational
changes in the protein, with a concomitant change of the ATPase
activity of P-gp [12,13]. The two nucleotide-binding domains
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ATPwith just one of the twoATP being hydrolyzed per transport
event. It is the ATP-binding and its subsequent hydrolysis that
provides the primary driving force for transport. The two NBD
cooperate with each other during drug transport [14].
Shapiro et al have determined the Km for P-gp transport of
Rho123 by plasma membrane vesicles. Their result for Km,
15μM, is not far from ours, 7.2±1.2 μM[15]. They also show co-
operation between ligands during binding to P-gp. Other
investigators who have studied the interaction between P-gp
and substrates by approaches such as P-gp ATPase activity
determination, substrate binding analysis, and accumulation
analysis [5,10,11] have often encountered co-operativity between
ligands during the pump's action, as we do in this study for
Rho123.
We also show that verapamil, as a typical inhibitor of P-gp,
inhibits Rho123 transport uncompetitively, which indicates that
Rho123 and verapamil bind with P-gp at different sites. This is
consistent with the research of Loo, Clarke and their colleagues,
which indicates that I340 (TM6), A841 (TM9), L975 (TM12),
V981 (TM12), and V982 (TM12) contribute to the binding of
Rhodamine dyes, while S222 (TM4), I306 (TM5), I868 (TM10),
and G872 (TM10) contribute to the binding of verapamil
[10,16,17].
Since P-gp-mediated drug efflux has been implicated as a
major factor contributing to multi-drug resistance (MDR) in
cancer chemotherapy, much effort has been put into the develop-
ment of P-gp inhibitor drugs to reverseMDR and also to regulate
the ADME of possible drugs. While photolabeling, cysteine-
scanning mutagenesis and P-gp ATPase analysis provide useful
approaches for the identification of substrate binding sites in P-
gp, transport kinetic studies such as described in the present
paper can make a useful addition to our knowledge and help us
understand the complex interactions between P-gp and its
transportable substrates.
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